Aluminum toxicokinetics in peritoneal dialysis patients

References

• Nolte E, Beck E, Winklhofer C, Steinhausen C. Compartmental model for aluminium biokinetics. Hum Exp Toxicol 2001; 20: 111–117.
   PubMed Web of Science ®Google Scholar
• Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J Environ Monit 2004; 6:375–403.
   PubMed Web of Science ®Google Scholar
• Steinhausen C, Kislinger G, Winklhofer C, Beck E, Hohl C, Nolte E, Ittel TH, Alvarez-Bruckmann MJ. Investigation of the aluminium biokinetics in humans: a 26Al tracer study. Food Chem Toxicol 2004; 42:363–371.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Levin A, Levin N. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1–201.
   PubMed Web of Science ®Google Scholar
• Ganrot PO. Metabolism and possible health effects of aluminum. Environ Health Perspect 1986; 65:363–441.
   PubMed Web of Science ®Google Scholar
• Greger JL, Sutherland JE. Aluminum exposure and metabolism. Crit Rev Clin Lab Sci 1997; 34:439–474.
   PubMed Web of Science ®Google Scholar
• Lin JL, Leu ML. Aluminium-containing agents may be toxic in predialysis chronic renal insufficiency patients. J Intern Med 1996; 240:243–248.
   PubMed Web of Science ®Google Scholar
• Boeckmann AJ, Beal SL, Sheiner LB. NONMEM VI Users Guides. Technical Report. Pharmacology DoC. San Francisco, CA: University of California; 2006.
   Google Scholar
• Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377–384.
   PubMedGoogle Scholar
• Jonsson EN, Karlsson MO. Xpose – an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51–64.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic–pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20:511–528.
   PubMedGoogle Scholar
• Mayor GH, Burnatowska-Hledin M. The metabolism of aluminum and aluminum-related encephalopathy. Semin Nephrol 1986; 6:1–4.
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Steer BM. Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol 1992; 2:1318–1327.
   PubMed Web of Science ®Google Scholar
• Priest ND, Newton D, Day JP, Talbot RJ, Warner AJ. Human metabolism of aluminium-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995; 14:287–293.
   PubMed Web of Science ®Google Scholar
• Montenegro J, Aguirre R, Saracho R, Moina I, Martinez I. Factors influencing serum aluminum in CAPD patients. Clin Nephrol 1998; 50:77–83.
   PubMed Web of Science ®Google Scholar
• Rottembourg J, Gallego JL, Jaudon MC, Clavel JP, Legrain M. Serum concentration and peritoneal transfer of aluminum during treatment by continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25:919–924.
   PubMed Web of Science ®Google Scholar
• Salusky IB, Coburn JW, Paunier L, Sherrard DJ, Fine RN. Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 1984; 105:717–720.
   PubMed Web of Science ®Google Scholar
• Burwen DR, Olsen SM, Bland LA, Arduino MJ, Reid MH, Jarvis WR. Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. Kidney Int 1995; 48: 469–474.
   PubMed Web of Science ®Google Scholar
• Mion C. Aluminium in continuous ambulatory peritoneal dialysis and post dilutional hemofiltration. Clin Nephrol 1985; 24:S88–93.
   PubMed Web of Science ®Google Scholar
• Fifield LK, Day JO, Oldham CL, Carling R. Study of the kinetics of aluminium absorption and excretion in humans. Department of Nuclear Physics, Annual Report 1997: Australian National University, Canberra; 1997: 97–101.
   Google Scholar
• Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, . Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev 2007; 10:1–269.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Passlick J, Busch T, Ohnesorge FK. Elimination of absorbed aluminum in patients undergoing continuous ambulatory peritoneal dialysis. J Toxicol Clin Toxicol 1988; 26:209–221.
   PubMed Web of Science ®Google Scholar
• Joffe P, Olsen F, Heaf JG, Gammelgaard B, Podenphant J. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1989; 32:133–138.
   PubMed Web of Science ®Google Scholar
• McCarthy JT, Kurtz SB, Mussman GV. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis. Am J Med 1987; 82:367–370.
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. Society SP. 4th. Stockholm: Swedish Pharmaceutical Press; 2006: 19–20.
   Google Scholar
• van Landeghem GF, de Broe ME, D'Haese PC. Al and Si: their speciation, distribution, and toxicity. Clin Biochem 1998; 31: 385–397.
   PubMed Web of Science ®Google Scholar
• Priest ND. The bioavailability and metabolism of aluminium compounds in man. Proc Nutr Soc 1993; 52:231–240.
   PubMed Web of Science ®Google Scholar
• Nayak P. Aluminum: impacts and disease. Environ Res 2002; 89: 101–115.
   PubMed Web of Science ®Google Scholar
• Ljunggren KG, Lidums V, Sjogren B. Blood and urine concentrations of aluminium among workers exposed to aluminium flake powders. Br J Ind Med 1991; 48:106–109.
   PubMedGoogle Scholar